Poly adenosine diphosphate ribose polymerase （PARP） inhibitors lead to synthetic lethality in homologous recombination repair-deficient （HRD） tumors by inhibiting DNA damage repair. Two PARP inhibitors，olaparib and talazoparib，have been approved for the salvage treatment of breast cancer susceptibility gene (BRCA) mutation，human epidermal growth factor receptor 2 （HER2） negative advanced breast cancer，and adjuvant treatment of early breast cancer. PAPR inhibitor single agent shows good antitumor activity and controllable safety. A number of clinical studies on PAPR inhibitors combined with chemotherapy，radiotherapy，antiangiogenic therapy and immunotherapy are being carried out. The indications of PARP inhibitors also extend from BRCA mutation to HRD，from ovarian cancer and breast cancer to other solid tumors，promising to benefit more patients in the future.